Home / Biotechnology / Plasma Fractionation Market By Product (Coagulation Factor Concentrates, Immunoglobulin, Albumin, Protease Inhibitors and Others), By Application (Neurology, Immunology, Hematology, Critical Care and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Plasma Fractionation Market By Product (Coagulation Factor Concentrates, Immunoglobulin, Albumin, Protease Inhibitors and Others), By Application (Neurology, Immunology, Hematology, Critical Care and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Mar 2019 | Report Code: 59635-03-19

Industry Outlook

The plasma fractionation market is set to reach from US$ 18,099.5 Mn in 2017 to US$ 33,386.6 Mn by 2026 at a compound annual growth rate (CAGR) of 7.1% during the forecast period from 2018 to 2026. Plasma fractionation is utilized for achieving large quantities of purified protein from human plasma. Researchers have been focusing diligently in understanding the role and significance of plasma derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market growth. 

Plasma Fractionation Market

Get a sample copy for more information

Rising prevalence of autoimmune disorders and technical innovation in deriving highly purified proteins from human plasma drive the immunoglobulin market growth

Immunoglobulin are reigning the product segment for plasma fractionation market. Technical innovations in deriving highly purified proteins from human plasma and rising prevalence of autoimmune disorders drive the immunoglobulin market growth. They are primarily of 5 classes (D,G,M,A,E) and several subclasses, responsible for consolidating the immune system. Albumin is gaining huge attention among researchers owing to its drug binding properties and its effective use as drug formulating agent, medical device coating, surgery sealants and vaccine ingredient.

Plasma Fractionation Market

Get a sample copy for more information

Increasing morbidity and lack of effective biological treatment drive the neurology applications market growth

According to World Health Organization (WHO), approximately 450 million people are reported annually to be suffering with mental illness. Neurology is dominating the application segment for plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and lack of effective biological treatment for neurological disorders. Recently newer antibodies have been developed to hinder the process of protein clusters misfolding which causes Alzheimer’s and Parkinson’s disease. Immunology application will be the fastest growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancement in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.

Plasma Fractionation Market

Get a sample copy for more information

Increasing number of patients suffering with chronic disease and presence of state of the art healthcare infrastructure drive the market growth in North America

North America is the supreme leader in global plasma fractionation market representing 38% share. The dominance is attributed to major factors such as increasing number of patients suffering with chronic diseases and presence of state of the art healthcare infrastructure. As per the statistics provided by Center for Disease Control and Prevention (CDC), 1 in every 6 American is living with chronic disease. Europe holds 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, Grifols, S.A. and supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% share and will showcase impressive growth during the forecast period on account of rise in per capital income and affordable reimbursement scenario for plasma fractionation products utilized during treatment of chronic ailments.

Plasma Fractionation Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026

Report Scope by Segments

The market segmentation comprises of by product, by application and geography.

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Product (2016–2026; US$ Mn)
 • Coagulation Factor Concentrates
 • Immunoglobulin
 • Albumin
 • Protease Inhibitors
 • Others

 By Application (2016–2026; US$ Mn)
 • Neurology
 • Immunology
 • Hematology
 • Critical Care
 • Others

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG., CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG., Sanquin and Shire, Plc.

Key questions answered in this report

  • What are the latest inorganic and organic market growth strategies adopted in plasma fractionation market?
  • Which biopharmaceutical companies are providing plasma fractionated products for treating chronic ailment?
  • What are the latest technical innovation associated with human plasma protein purification?
  • What are the clinical use of immunoglobulin?
  • What is the prevalence rate of neurological disorders and its treatment by using antibodies?
  • What is the plasma fractionation market growth in developing nation such as Asia Pacific, Latin America and Middle East & Africa?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PF Market Portraiture
2.2. Global PF Market, by Product, 2017 (US$ Mn)
2.3. Global PF Market, by Application, 2017 (US$ Mn)
2.4. Global PF Market, by Geography, 2017 (US$ Mn)

Chapter 3. Plasma Fractionation (PF) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global PF Market, by Key Players, 2017

Chapter 4. Global Plasma Fractionation (PF) Market, by Product
4.1. Overview
4.2. Coagulation Factor Concentrates
4.3. Immunoglobulin
4.4. Albumin
4.5. Protease Inhibitors
4.6. Others

Chapter 5. Global Plasma Fractionation (PF) Market, by Application
5.1. Overview
5.2. Neurology
5.3. Immunology
5.4. Hematology
5.5. Critical Care
5.6. Others

Chapter 6. Global Plasma Fractionation (PF) Market, by Geography
6.1. Overview
6.2. North America PF Market Analysis, 2016 – 2026
6.2.1. North America PF Market, by Product, 2016 – 2026 (US$ Mn)
6.2.2. North America PF Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America PF Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe PF Market Analysis, 2016 – 2026
6.3.1. Europe PF Market, by Product, 2016 – 2026 (US$ Mn)
6.3.2. Europe PF Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific PF Market Analysis, 2016 – 2026
6.4.1. Asia Pacific PF Market, by Product, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific PF Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America PF Market Analysis, 2016 – 2026
6.5.1. Latin America PF Market, by Product, 2016 – 2026 (US$ Mn)
6.5.2. Latin America PF Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa PF Market Analysis, 2016 – 2026
6.6.1. MEA PF Market, by Product, 2016 – 2026 (US$ Mn)
6.6.2. MEA PF Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Baxter International, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Biotest AG
7.3. CSL Limited
7.4. Grifols, S.A.
7.5. Green Cross Corporation
7.6. Japan Blood Products Organization
7.7. Kedrion Biopharma, Inc.
7.8. Octapharma AG
7.9. Sanquin
7.10. Shire, Plc.

* PF - Plasma Fractionation

FIG. 1 : Plasma Fractionation (PF) Market: Research Methodology
FIG. 2 : PF: Market Segmentation
FIG. 3 : Global PF Market, by Product, 2017 (US$ Mn)
FIG. 4 : Global PF Market, by Application, 2017 (US$ Mn)
FIG. 5 : Global PF Market, by Geography, 2017 (US$ Mn)
FIG. 6 : Attractive Investment Proposition: by Geography, 2017
FIG. 7 : Competitive Analysis: Global PF Market, by Key Players, 2017
FIG. 8 : Global Coagulation Factor Concentrates Market for PF, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Immunoglobulin Market for PF, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Albumin Market for PF, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Protease Inhibitors Market for PF, 2016 – 2026 (US$ Mn)
FIG. 12 : Global Other Products Market for PF, 2016 – 2026 (US$ Mn)
FIG. 13 : Global Neurology Market for PF, 2016 – 2026 (US$ Mn)
FIG. 14 : Global Immunology Market for PF, 2016 – 2026 (US$ Mn)
FIG. 15 : Global Hematology Market for PF, 2016 – 2026 (US$ Mn)
FIG. 16 : Global Critical Care Market for PF, 2016 – 2026 (US$ Mn)
FIG. 17 : Global Other Applications Market for PF, 2016 – 2026 (US$ Mn)
FIG. 18 : U.S. PF Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Canada PF Market, 2016 – 2026 (US$ Mn)
FIG. 20 : U.K. PF Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Germany PF Market, 2016 – 2026 (US$ Mn)
FIG. 22 : Rest of Europe PF Market, 2016 – 2026 (US$ Mn)
FIG. 23 : China PF Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Japan PF Market, 2016 – 2026 (US$ Mn)
FIG. 25 : Rest of Asia Pacific PF Market, 2016 – 2026 (US$ Mn)
FIG. 26 : Brazil PF Market, 2016 – 2026 (US$ Mn)
FIG. 27 : Mexico PF Market, 2016 – 2026 (US$ Mn)
FIG. 28 : Rest of Latin America PF Market, 2016 – 2026 (US$ Mn)
FIG. 29 : GCC PF Market, 2016 – 2026 (US$ Mn)
FIG. 30 : Rest of MEA PF Market, 2016 – 2026 (US$ Mn)

TABLE 1 : Global Plasma Fractionation (PF) Market Portraiture
TABLE 2 : Global PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 3 : Global PF Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 4 : Global PF Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 : North America PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 6 : North America PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 7 : North America PF Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 : Europe PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 9 : Europe PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 10 : Europe PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 : Asia Pacific PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 12 : Asia Pacific PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 13 : Asia Pacific PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 : Latin America PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 15 : Latin America PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 16 : Latin America PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 : Middle East and Africa PF Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 18 : Middle East and Africa PF Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 19 : Middle East and Africa PF Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 : Baxter International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Biotest AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : CSL Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Grifols, S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 : Green Cross Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 : Japan Blood Products Organization: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 : Kedrion Biopharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 : Octapharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 : Sanquin: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 : Shire, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients